ARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc.
http://www.ariad.com/ Develops drugs which block intracellular signal transduction pathways for treating solid tumors and hematologic malignancies. Includes kits available, technology overview and investor data from Cambridge, Massachusetts. (Nasdaq: ARIA) Cancer > Research and Development ARIAD is developing breakthrough medicines that regulate cell-signaling pathways implicated in cancer. Our pipeline includes a series of small molecule product candidates that provide targeted and highly potent anti-cancer activity to treat solid tumors and hematologic cancers, as well as the spread of tumors to distant sites. Our lead candidate — ridaforolimus, a novel mTOR inhibitor—has been given fast track designation by the FDA for the treatment of soft-tissue and bone sarcomas.ARIAD is dedicated to developing new, breakthrough therapies with the potential to transform the lives of patients with difficult-to-treat cancers. ARIAD scientists and clinical researchers are experts with specialized knowledge in oncology’s most challenging areas, including blood cancers Signal transduction Gene regulation Signal transduction inhibitors Regulated cell therapy Regulated gene transcription
Write a Review
Add to My Favorite
Refer it to Friend
Report Broken Link
Google Ads
Other links at Cancer > Research and Development
Discovers and develops immunologically based therapeutic anticancer products. Includes progress of clinical trials, and data for investors from company based in Seattle, Washington. (Nasdaq: DNDN)
Category:
Develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. Includes overview of clinical trials, investor information and news from company in Plymouth Meeting, Pennsylvania. (Nasdaq: GENR)
Category:
Focused on utilizing functional genomics and proteomics to develop therapeutic agents and diagnostic tests for diseases with substantial unmet clinical need.
Category:
Main Category
14
100
31
5
50
7
11
40
166
20
59
76
24
75
110
142
7
8
13
30
66
Join Mailing List
Joining mailing list will entitle you
to receive occasional emails informing you of news and
updates to the site and any special offers that may be
of interest to you.
Top 10
Directory Statistics
Links: 1054
Categories: 36
Pagerank Statistics
Yahoo News